Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim of the program is to give selected change-makers around the world new opportunities to grow and transform great ideas into powerful impact solutions that help to improve the lives of millions.

Start Alliance Berlin: Digital Health is a two-week program taking place in November 2018 which is intended to help startups from BEIJING, DUBAI, NEW YORK, LONDON, PARIS, SHANGHAI, TEL AVIV, VIENNA and WARSAW to expand their business to Germany via BERLIN. In this edition the program will focus on Digital Health and related topics.

Philanthropist Bill Gates and the Alzheimer's Drug Discovery Foundation (ADDF) co-founder Leonard Lauder have announced a new initiative, Diagnostics Accelerator, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias.

Cerner has announced the plans to significantly grow its Dublin hub for research and development. Working with the support of the Irish Government through IDA Ireland, will be created 50 new roles focused on R&D and the improvement of data intelligence and population health management for the European clients.

The European Data Protection Supervisor (EDPS), in partnership with the Data Protection Authorities of Austria, Ireland and Schleswig-Holstein and supported by the Internet Privacy Engineering Network (IPEN), is pleased to announce the launch of the EDPS-IPEN Privacy by Design contest for mobile Health (mHealth) applications.

NHS professionals at a North West trust have been shortlisted for the prestigious national Patient Safety Awards, following important work around rapid response for deteriorating patients. The team at St Helens and Knowsley Teaching Hospitals NHS Trust innovated with their Patientrack electronic observations system to tackle a major cause of complications for patients on intravenous fluids and electrolytes.

The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company Ltd. today announced that using IT-based drug discovery technologies, which entails computer-based virtual design and evaluation, they have successfully created new small molecule compounds that can inhibit cancer-causing "target proteins," and that demonstrate promise against cancers that have shown resistance to existing drugs.